NEAT1 and hepatocellular carcinoma: As shown in Figure 3, the effects of increased NEAT1 expression on OS was shown in patients with colorectal cancer (HR = 1.91, 95% CI = 1.41–2.58, P < 0.001), NSCLC (HR = 1.35, 95% CI = 1.04–1.76, P = 0.03), HCC (HR = 1.13, 95% CI = 0.55–2.33, P = 0.75), gastric cancer (HR = 1.61, 95% CI = 1.03–2.53, P = 0.04), ESCC (HR = 1.92, 95% CI = 1.40–2.63, P < 0.001), glioma (HR = 1.48, 95% CI = 0.87–2.71, P = 0.14), ovarian cancer (HR = 1.41, 95% CI = 1.11–1.79, P = 0.004), and nasopharyngeal carcinoma (HR = 1.39, 95% CI = 1.06–1.83, P = 0.02).